BBIO Attruby: $222M Q2, $15B Cap, 3 Launches to Justify It

BridgeBio Pharma closed August 28 at $76.60, a market cap near $15 billion. Its only commercial product, Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, posted $222.4 million in US net product revenue in Q2 2026, up 211% from $71.5 million a year earlier. Total revenue hit $243.7 million, up 120%. The launch is working. The question is whether one fast-growing drug can carry a $15 billion valuation while three more launches wait in the wings.

The launch numbers, quarter by quarter

Attruby was approved November 22, 2024 as the first and only near-complete TTR stabilizer, defined as 90% or greater stabilization of the transthyretin tetramer. It generated $502.1 million in total 2025 revenue. Then it accelerated: $180.6 million in Q1 2026, up 392% year over year, and $222.4 million in Q2 2026, a $35 million sequential step up. Royalty revenue from Beyonttra, the ex-US brand, added $15.4 million in Q2, up from $1.6 million a year earlier as the European and Japanese launches spool up.

BridgeBio reaffirmed guidance of $1 billion plus in global Attruby and Beyonttra sales for 2026. At the current trajectory, the drug exits the year at a run rate above $1 billion annualized. The company claims 23% share of the ATTR-CM market and calls Attruby the fastest-growing brand in the space. Those are not vanity metrics. Pfizer’s tafamidis, the incumbent since 2019, is the wall Attruby has to climb, and a 23% share this early is a genuine threat to that wall.

The addressable market is the reason the ramp compounds. ATTR-CM affects an estimated 300,000 to 500,000 people worldwide, a progressive heart failure caused by amyloid deposits stiffening the heart muscle, and the overwhelming majority are diagnosed late or never. Tafamidis turned that underdiagnosed population into a multi-billion-dollar franchise for Pfizer. Attruby is attacking the same population with a better stabilizer at a comparable price. That is the setup for a launch that keeps compounding.

The mechanism moat is real

Acoramidis is not a me-too. Tafamidis stabilizes transthyretin enough to slow amyloid formation. Acoramidis mimics the disease-protective Thr119Met mutation and achieves near-complete stabilization, which a JACC analysis confirmed at 92.9% versus 49.1% for tafamidis across 51 patient samples. It is roughly four times more potent as a stabilizer at clinical concentrations.

The registrational ATTRibute-CM trial enrolled 632 patients and met its hierarchical primary endpoint, a composite of all-cause mortality, cardiovascular hospitalization, NT-proBNP, and six-minute walk distance at 30 months, with a win ratio of 1.8 and a p-value below 0.0001. That is a cardiovascular outcomes benefit, not a biomarker story. It is the same class of endpoint that got tafamidis approved on ATTR-ACT.

The differentiation now extends beyond the heart. Data published in Circulation: Heart Failure in July showed early and sustained kidney protection in ATTR-CM, including an improvement in estimated glomerular filtration rate slope and a reduction in urinary albumin-to-creatinine ratio. Renal decline is a meaningful secondary driver of ATTR-CM outcomes, and it is a dimension tafamidis has not been shown to move. Every incremental data set widens the clinical argument for switching.

The competitive fight just got easier

The ATTR-CM field was supposed to crowd up. Instead it thinned. Ionis and AstraZeneca’s eplontersen, a TTR silencer already approved for polyneuropathy, failed its CARDIO-TTRansform Phase 3 in cardiomyopathy in July, missing the composite of cardiovascular death and recurrent events through Week 140. The largest ATTR-CM trial ever run, 1,432 patients, could not show incremental benefit on top of background stabilizers. That failure and what it means here is covered in a prior piece.

That is doubly good for Attruby. It removes a competitor from the cardiomyopathy indication, and it validates the thesis that stabilization, Attruby’s mechanism, is the relevant lever for the heart, while silencing TTR production on top of a stabilizer adds little. The remaining wildcard is Alnylam’s vutrisiran, a quarterly TTR silencer that read out positive in HELIOS-B, but eplontersen’s miss shows silencers face a higher bar than the stabilizer-first standard of care Attruby is displacing.

What the launch funds

Attruby is the financial anchor under everything else BridgeBio is doing, and the company is spending the ramp to fund a launch trifecta. Three programs moved from data into active FDA review in the same quarter. BBP-418 for LGMD2I has a November 27, 2026 PDUFA. Encaleret for ADH1 has a May 2027 PDUFA, covered in the encaleret NDA piece. Infigratinib for achondroplasia is also under review. Management has pegged peak sales at $1 billion each for BBP-418 and encaleret and $2 billion for infigratinib.

That is the bull case in one sentence: a $1 billion-plus Attruby franchise funding three launches that could collectively add another $4 billion in peak sales. BridgeBio finished the quarter with a $1.7 billion cash position after a preferred equity financing, enough to fund all three launches without a dilutive secondary. BBP-418 is the near-term catalyst, covered in the BBP-418 PDUFA analysis, and the pan-KRAS program adds a longer-dated oncology option covered in BBO-11818 versus RVMD.

The valuation: the multiple is the risk

At $15 billion, BridgeBio trades at roughly 15x forward revenue on a drug growing triple digits. Compare BioMarin at about $11.4 billion for $2.8 billion in annual revenue, roughly 4x sales. Compare Ascendis Pharma at about $16.6 billion with Yorvipath on the market. A 15x forward revenue multiple is a growth-stock multiple applied to a four-bet portfolio, not a value multiple. BridgeBio is priced like the platform has already delivered all three launches plus Attruby’s peak.

The arithmetic says the multiple is the risk, not the launch. If Attruby peaks at $2 to $3 billion in US sales and you apply a 4x peak sales multiple, the drug is worth $8 to $12 billion on its own. That means $3 to $7 billion of the current market cap is the option value of BBP-418, encaleret, and infigratinib. The market is paying for near-perfect execution across four programs.

The specific risks are concrete. First, payer pressure. Attruby lists near $244,000 a year, and ICER has already said TTR stabilizers should cost $13,600 to $39,000 a year to be cost effective, an 85% to 95% cut. Net price erosion is a when, not an if. Second, tafamidis is entrenched, has a decade of outcomes data, and Pfizer will defend it. Third, launching three rare disease drugs simultaneously is an execution strain even for a company that has done it once. For the mechanics of how a launch’s first 90 days set the trajectory, see the post-approval first 90 days framework.

The verdict

Attruby is a real franchise and the launch is ahead of schedule. The mechanism is genuinely better than tafamidis, the registrational data is a hard outcomes win, and eplontersen’s failure just handed BridgeBio a thinner competitive field. At $1 billion plus in 2026 and a $2 to $3 billion peak path, Attruby alone supports $10 to $12 billion of the valuation.

But at $76.60, you are paying $15 billion, and the remaining $3 to $7 billion is a bet that BBP-418, encaleret, and infigratinib all launch on time and hit their peak sales targets. That is a lot of perfection to price in. Hold existing positions and add on a pullback toward $70, not chase at $76. The BBP-418 PDUFA on November 27 is the next binary that can move the stock either way. If it clears, the three-launch thesis starts converting from option value to revenue, and the multiple has room to run. If any launch stumbles, a $15 billion market cap built on four bets gets re-rated hard.

Source: BridgeBio Q2 2026 results | NEJM, ATTRibute-CM